Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 279

Results For "MP"

10013 News Found

EY to acquire life science tech firm Aqurance
Technology | October 14, 2025

EY to acquire life science tech firm Aqurance

Acquisition strengthens EY’s Veeva Centers of Excellence, expanding clinical, regulatory, and commercial services for global pharma and biotech companies


Biocon gets 1 USFDA observation for Cranbury site
Drug Approval | October 14, 2025

Biocon gets 1 USFDA observation for Cranbury site

The Cranbury facility represents a strategic advancement of the company's operations in the Unted States


Corning and SGD Pharma inaugurate glass tubing facility in Telangana
News | October 14, 2025

Corning and SGD Pharma inaugurate glass tubing facility in Telangana

The new plant will manufacture high-quality Type I borosilicate glass tubing


Fredun Pharmaceuticals launches India's first pure Jain dog biscuit
News | October 14, 2025

Fredun Pharmaceuticals launches India's first pure Jain dog biscuit

This innovation reinforces Fredun's commitment to creating a 360 degree pet wellness ecosystem


Mankind Pharma MD Rajeev Juneja appointed new president of PHDCCI
People | October 14, 2025

Mankind Pharma MD Rajeev Juneja appointed new president of PHDCCI

Anil Gupta has been appointed as the Senior Vice President, and Sanjay Singhania has taken charge as the Vice President of PHDCCI


BioMed X launches women’s health R&D accelerator ‘XFem labs’ in Germany
R&D | October 14, 2025

BioMed X launches women’s health R&D accelerator ‘XFem labs’ in Germany

First research project, supported by the Gates Foundation, focuses on developing non-hormonal contraceptives for women in low- and middle-income countries


FDA approves AbbVie’s Upadacitinib for treatment of inflammatory bowel disease
Drug Approval | October 14, 2025

FDA approves AbbVie’s Upadacitinib for treatment of inflammatory bowel disease

Updated indication expands treatment options for patients with ulcerative colitis and Crohn’s disease when tumor necrosis factor (TNF) blockers are clinically inadvisable


AbbVie showcases breakthrough ADC hard-to-treat cancers data at ESMO 2025
Clinical Trials | October 14, 2025

AbbVie showcases breakthrough ADC hard-to-treat cancers data at ESMO 2025

New results from telisotuzumab adizutecan (Temab-A) and ABBV-706 demonstrate continued progress in AbbVie's antibody-drug conjugate (ADC) portfolio targeting difficult-to-treat cancers


Vasa Therapeutics secures FDA IND clearance to advance VS-041 into clinical trial for HFpEF
Drug Approval | October 14, 2025

Vasa Therapeutics secures FDA IND clearance to advance VS-041 into clinical trial for HFpEF

IND clearance enables initiation of Phase 1c clinical trial in HFpEF patients with elevated endotrophin levels